An immunohistochemical and genetic study of <i>BRAF</i><sup><i>V600E</i></sup> mutation in Japanese patients with ameloblastoma
Mai Seki, Takaaki Sano, Kenta Ito, Satoshi Yokoo, Tetsunari Oyama
Abstract
Ameloblastoma is an odontogenic tumor of the jaw. It most frequently occurs in the mandible, and less often in the maxilla. Mandibular ameloblastoma harbors a BRAF mutation that causes a valine (V) to glutamic acid (E) substitution at codon 600 ( BRAF V600E ). We examined specimens from 32 Japanese patients to detect the prevalence of the BRAF V600E mutation, and to evaluate the relationship between immunohistochemical (IHC) expression and genetic results, of BRAF V600E+ ameloblastoma. Among the 32 cases, 22 (69%) were IHC positive for BRAF V600E protein, and 10 (31%) were IHC negative; and polymerase chain reaction showed 16 of 21 tested cases (76%) carried the BRAF V600E mutation. Our findings indicate that that samples that stain IHC positive for BRAF V600E protein are more likely to carry the BRAF V600E mutation. These results support assessments for BRAF mutations, and the use of BRAF inhibitors as targeted therapy for ameloblastoma in Japanese patients.